203 related articles for article (PubMed ID: 36044174)
21. Icatibant as acute treatment for hereditary angioedema in adults.
Farkas H
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):779-88. PubMed ID: 27123689
[TBL] [Abstract][Full Text] [Related]
22. Facilitating home-based treatment of hereditary angioedema.
Bernstein JA; Riedl M; Zacek L; Shapiro RS
Allergy Asthma Proc; 2015; 36(2):92-9. PubMed ID: 25551795
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and therapeutic management of hereditary angioedema due to C1-inhibitor deficiency: the Italian experience.
Cancian M;
Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):383-91. PubMed ID: 26106828
[TBL] [Abstract][Full Text] [Related]
24. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency.
Wu MA; Zanichelli A; Mansi M; Cicardi M
Expert Opin Pharmacother; 2016; 17(1):27-40. PubMed ID: 26512744
[TBL] [Abstract][Full Text] [Related]
25. Bradykinin mediated gastrointestinal edema as a cause of abdominal attacks in patients with hereditary angioedema due to C1-inhibitor deficiency.
Obtulowicz P; Piotrowicz-Wojcik K; Dyga W; Stobiecki M; Popiela T; Obtulowicz K
J Physiol Pharmacol; 2022 Apr; 73(2):. PubMed ID: 36193964
[TBL] [Abstract][Full Text] [Related]
26. Acute Management of Hereditary Angioedema Attacks.
Katelaris CH
Immunol Allergy Clin North Am; 2017 Aug; 37(3):541-556. PubMed ID: 28687108
[TBL] [Abstract][Full Text] [Related]
27. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
Otani IM; Lumry WR; Hurwitz S; Li HH; Craig TJ; Holtzman NS; Iandoli MI; Tucker J; Riedl MA; Zuraw BL; Banerji A
J Allergy Clin Immunol Pract; 2017; 5(2):442-447.e1. PubMed ID: 27818136
[TBL] [Abstract][Full Text] [Related]
28. Real-world reporting rates of administration-site reactions with on-demand treatment of hereditary angioedema attacks.
Tachdjian R; Savic S; Fridman M; Frade JP; Fasehun M; Audhya PK
Allergy Asthma Proc; 2024 Jan; 45(1):37-43. PubMed ID: 37993116
[No Abstract] [Full Text] [Related]
29. Progress in the emergency management of hereditary angioedema: focus on new treatment options in the United States.
Bernstein JA; Moellman JJ
Postgrad Med; 2012 May; 124(3):91-100. PubMed ID: 22691903
[TBL] [Abstract][Full Text] [Related]
30. New Treatments for Hereditary Angioedema.
Johnson NM; Phillips MA
Skin Therapy Lett; 2018 Jan; 23(1):6-8. PubMed ID: 29357215
[TBL] [Abstract][Full Text] [Related]
31. The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema.
Maurer M; Aberer W; Caballero T; Bouillet L; Grumach AS; Botha J; Andresen I; Longhurst HJ;
Clin Exp Allergy; 2022 Sep; 52(9):1048-1058. PubMed ID: 35861129
[TBL] [Abstract][Full Text] [Related]
32. Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.
Maurer M; Bork K; Martinez-Saguer I; Aygören-Pürsün E; Botha J; Andresen I; Magerl M
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):163-169. PubMed ID: 30176179
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency.
Zanichelli A; Mansi M; Periti G; Cicardi M
Expert Rev Clin Immunol; 2013 May; 9(5):477-88. PubMed ID: 23634741
[TBL] [Abstract][Full Text] [Related]
34. How satisfactory is on-demand icatibant from the patients' perspective in real life?
Beyaz S; Demir S; Oztop N; Colakoglu B; Buyukozturk S; Gelincik A
Allergy Asthma Proc; 2022 Mar; 43(2):148-154. PubMed ID: 35317892
[No Abstract] [Full Text] [Related]
35. Current management options for hereditary angioedema.
Bork K
Curr Allergy Asthma Rep; 2012 Aug; 12(4):273-80. PubMed ID: 22729959
[TBL] [Abstract][Full Text] [Related]
36. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A
Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
[TBL] [Abstract][Full Text] [Related]
37. Switch to icatibant in a patient affected by hereditary angioedema with high disease activity: a case report.
Firinu D; Barca MP; Serusi L; Lorrai MM; Peralta MM; Manconi PE; Del Giacco SR
Int J Immunopathol Pharmacol; 2012; 25(1):269-73. PubMed ID: 22507340
[TBL] [Abstract][Full Text] [Related]
38. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.
Malbrán A; Riedl M; Ritchie B; Smith WB; Yang W; Banerji A; Hébert J; Gleich GJ; Hurewitz D; Jacobson KW; Bernstein JA; Khan DA; Kirkpatrick CH; Resnick D; Li H; Fernández Romero DS; Lumry W
Clin Exp Immunol; 2014 Aug; 177(2):544-53. PubMed ID: 24749847
[TBL] [Abstract][Full Text] [Related]
39. Management and prevention of hereditary angioedema attacks.
Lumry WR
Am J Manag Care; 2013 Jun; 19(7 Suppl):s111-8. PubMed ID: 23844783
[TBL] [Abstract][Full Text] [Related]
40. Update on the acute treatment of hereditary angioedema.
Riedl MA
Allergy Asthma Proc; 2011; 32(1):11-6. PubMed ID: 21262093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
